Tourmaline Bio (TRML)

• Market cap: $458M
• 1 day: 5.84%
• 5 days: -3.15%
• 1 month: 13.15%
• 3 months: 4.94%
• 6 months: -35.01%
• Year to date: -16.62%
• 1 year: 8.72%
• 5 years: 5.91%
• 10 years: 5.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Employees: 74

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

10% more funds holding

Funds holding: 92 [Q3] → 101 (+9) [Q4]

7.14% more ownership

Funds ownership: 82.03% [Q3] → 89.17% (+7.14%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]

14% less capital invested

Capital invested by funds: $541M [Q3] → $464M (-$77.1M) [Q4]

65% less call options, than puts

Call options by funds: $89K | Put options by funds: $251K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $43 150% upside
• Avg. target: $55 221% upside
• High target: $70 307% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Daniil Gataulin 22% 1-year accuracy 11 / 50 met price target	307% upside $70	Buy Initiated	23 Apr 2025
Wedbush Laura Chico 13% 1-year accuracy 6 / 47 met price target	150% upside $43	Outperform Maintained	14 Mar 2025
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target	191% upside $50	Buy Maintained	14 Mar 2025
LifeSci Capital Jimmy Shan 38% 1-year accuracy 3 / 8 met price target	237% upside $58	Outperform Initiated	24 Feb 2025